智通财经网·2025-07-29 01:33Core Viewpoint - WuXi AppTec (02359) reported strong interim results for the six months ending June 30, 2025, with significant revenue and profit growth, leading to a positive market reaction with a share price increase of over 4% [1] Group 1: Financial Performance - The company achieved a revenue of 20.799 billion RMB, representing a year-on-year increase of 20.6% [1] - Gross profit reached 9.112 billion RMB, up 36% year-on-year [1] - Net profit attributable to shareholders was 8.287 billion RMB, marking a substantial increase of 95.5% year-on-year [1] - Basic earnings per share were reported at 2.92 RMB, with an interim dividend proposed at 3.5 RMB per 10 shares [1] Group 2: Order Backlog and Revenue Sources - As of June 30, 2025, the company had a backlog of orders amounting to 56.69 billion RMB, which is a 37.2% increase year-on-year [1] - Revenue from ongoing operations was 20.41 billion RMB, with contributions from various regions: - Revenue from U.S. clients was 14.03 billion RMB, up 38.4% year-on-year [1] - Revenue from European clients was 2.33 billion RMB, increasing by 9.2% [1] - Revenue from Chinese clients was 3.15 billion RMB, down 5.2% [1] - Revenue from other regions was 0.90 billion RMB, up 7.6% [1] Group 3: Business Segments - The chemical business generated revenue of 16.3 billion RMB, reflecting a year-on-year growth of 33.5% [2] - The small molecule drug discovery (R) business has been a key driver, with over 440,000 new compounds successfully synthesized and delivered to clients in the past twelve months [2] - The company has implemented a "follow the customer" and "follow the molecule" strategy, establishing strong partnerships with global clients, which supports the ongoing growth of its CRDMO business [2]